- Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
-
Nakajima A, Fujimaki M, Arai Y, Emori K
- KMID: 2531217
- J Neurogastroenterol Motil.
- 2022 Jul;28(3):431-441.
- doi: 10.5056/jnm20263
Background/Aims Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of... -
- CITED
-
- Close
- SHARE
-
- Close
- A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
-
Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M
- KMID: 2509979
- Osteoporos Sarcopenia.
- 2020 Dec;6(4):191-198.
- doi: 10.1016/j.afos.2020.11.002
Objectives This postmarketing study aims to evaluate the safety and effectiveness of oral administration of risedronate at 75 mg once monthly for 36 months in patients with osteoporosis in Japan. Methods Participants were... -
- CITED
-
- Close
- SHARE
-
- Close
